Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med LifeLTS:0RO5 70 3-1 Month Momentum % is 42.55% as of Aug. 15, 2026. GuruFocus rates LTS:0RO5 with a GF Score™ of 70/100 and a GF Value™ of lei1.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Med Life ranks better than 59.37% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-15), Med Life's 3-1 Month Momentum % is 42.55%.
The industry rank for Med Life's 3-1 Month Momentum % or its related term are showing as below:
LTS:0RO5's 3-1 Month Momentum % is ranked better than 59.37% of 672
companies
in the Healthcare Providers & Services industry
Industry Median: -2.255
vs LTS:0RO5: 42.55
Med Life (LTS:0RO5) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Med Life 3-1 Month Momentum % Related Terms
LTS:0RO5 vs HCA, THC, DVA: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Med Life's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Med Life's 3-1 Month Momentum % falls into.
Med Life (LTS:0RO5) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (LTS:0RO5) has a 3-1 Month Momentum % of 42.55% as of Aug. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Med Life and its competitors. According to the industry distribution chart, Med Life ranks #273 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 40.6%.
Is Med Life's 3-1 Month Momentum % too high?
Med Life's current 3-1 Month Momentum % is 42.55%. Based on the distribution chart, Med Life ranks #273 out of 672 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Med Life has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's 3-1 Month Momentum % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #273 out of 672 companies for 3-1 Month Momentum %. This puts Med Life in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Med Life and its competitors. Med Life's current 3-1 Month Momentum % is 42.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.41, compared to a current price of lei11.62 — trading 724.1% above its estimated fair value. The current 3-1 Month Momentum % is 42.55%. Med Life's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current 3-1 Month Momentum % is 42.55% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.62 is trading 724.1% above its estimated GF Value™ of lei1.41.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
3-1 Month Momentum %: 42.55%
GF Value™: lei1.41 vs. price of lei11.62 (724.1% above fair value)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
70GF Score
Get the complete analysis for LTS:0RO5
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
